In response to the ongoing COVID-19 pandemic, Erba Mannheim today launched the 
ErbaLisa COVID-19 IgM ELISA kit for detection of IgM antibodies to SARS-CoV-2. 

IgM antibodies are produced first and detectable during disease onset, so using 
the new assay in combination with Erba's existing ErbaLisa COVID-19 IgG ELISA 
will detect both early and late phases of the immune response.

The ready-to-use ELISA kits will allow qualitative and semi-quantitative 
detection of IgG/M antibodies.

Nikhil Vazirani, MD of Erba Mannheim, said: "We are working tirelessly to offer 
more options to clinicians and laboratories with which to gain an advantage in 
responding to this unprecedented global health crisis."

With full CE certification, products are now available through Erba's global 
distribution network, including in the USA.

Learn more: https://erbalisacovid19.erbamannheim.com/.

About Erba Mannheim

Erba Mannheim is a global company focused on delivering innovative, affordable 
and sustainable healthcare solutions to developing nations. Providing clinical 
diagnostic products in over 100 countries, Erba uses a combination of cutting 
edge European and American R&D with efficient low-cost manufacturing to make 
innovative technologies accessible in all resource settings.

Source: Erba Mannheim